Abstract: A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium (Re), and the bidentate ligand containing another nitrogen atom, either in a ring or not in a ring, bound to the rhenium (Re); and L1, L2, L3, and L4 are neutral ligands with at least one neutral ligand being an isonitrile ligand of the formula —CN—R, wherein R is an aliphatic or aromatic hydrocarbon group containing 1-20 carbon atoms; and X? represents a non-coordinating monovalent anion; wherein the bidentate ligand and R are optionally substituted by one or more groups selected from (i)-(xi) as further discussed above. Methods for treating a condition that benefits from ER stress induction, such as cancer, by administering the above rhenium complex are also disclosed.

Abstract: Zr-based metal-organic frameworks (Zr-MOFs) independently comprising the following formula and/or structure: Zr6O4(OH)4(polycarboxylate)6, and methods of making and using same. In various examples, a method produces a Zr-MOF or Zr-MOFs. In various examples, a Zr-MOF is a hydrogen sulfide (H2S)-loaded Zr-MOF. In various examples, a method produces a (H2S)-loaded Zr-MOF or (H2S)-loaded Zr-MOF. In various examples, a Zr-MOF or Zr-MOFs is/are used to deliver H2S to an aqueous environment, a solvent, or the like. In various examples, a Zr-MOF or Zr-MOFs is/are used to deliver H2S to an aqueous environment, a solvent, or the like. In various examples, a Zr-MOF or Zr-MOFs is/are used to deliver H2S to an individual, such as, for example, an individual suffering from or at risk of an ischemia-reperfusion injury, inflammation, a wound, or the like, or any combination thereof.

Abstract: A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium (Re), and the bidentate ligand containing another nitrogen atom, either in a ring or not in a ring, bound to the rhenium (Re); and L1, L2, L3, and L4 are neutral ligands with at least one neutral ligand being an isonitrile ligand of the formula —CN—R, wherein R is an aliphatic or aromatic hydrocarbon group containing 1-20 carbon atoms; and X? represents a non-coordinating monovalent anion; wherein the bidentate ligand and R are optionally substituted by one or more groups selected from (i)-(xi) as further discussed above. Methods for treating a condition that benefits from ER stress induction, such as cancer, by administering the above rhenium complex are also disclosed.

Abstract: Compositions, kits, and methods for treatment of cancers are generally provided. In some embodiments, the compositions, kits, and methods comprise a platinum (e.g., Pt(II) or Pt(IV)) compound associated with a ligand (e.g., a beta-diketonate ligand) comprising a targeting moiety. Methods of synthesizing platinum (e.g., Pt(II) or Pt(IV)) compounds associated with a ligand comprising a targeting moiety are also provided.

Abstract: Compositions, kits, and methods for treatment of cancers are generally provided. In some embodiments, the compositions, kits, and methods comprise a platinum (e.g., Pt(II) or Pt(IV)) compound associated with a ligand (e.g., a beta-diketonate ligand) comprising a targeting moiety. Methods of synthesizing platinum (e.g., Pt(II) or Pt(IV)) compounds associated with a ligand comprising a targeting moiety are also provided.

Abstract: The present invention is a platinum(II) compound comprising a beta-diketonate ligand represented by the following general formula: Or general formula: wherein R1 and R2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted; R3 and R4 are independently selected from the group consisting of ammonia, an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine, or R3 and R4 can be joined together to form a bidentate ligand Z and Y are independently selected from the group consisting of O and S, provided at least one of Z and Y is S; and X— is a counterion. These compounds are useful in the treatment of cancer.

Abstract: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a compound including platinum (e.g., platinum(II) or platinum(IV)) compound comprising a beta-diketonate ligand.